Researchers at MIT have unveiled a way to temporarily reboot aging immune systems, using a targeted mRNA therapy that turns ...

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the closing of the $25M final tranche to its Series B ...